Zydus Lifesciences gets EIR from USFDA for Pharmez facility
Ahmedabad: Zydus Lifesciences has recently announced thatthe Company has received the Establishment Inspection Report (EIR) from the United States Foos and Drug Administration (USFDA) for the inspection conducted at its manufacturing facility located at Pharmez, Ahmedabad,from March 20 to 24, 2023.
The inspection has been classified as Voluntary Action Indicated (VAI). The EIR report indicates that the inspection is closed.
Medical Dialogues team had earlier reported that the USFDA had concluded an inspection with three observations at the Company's said manufacturing facility.
Read also: USFDA issues 3 observations for Zydus Lifesciences Ahmedabad facility
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The Company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Read also: Zydus Lifesciences bags USFDA tentative nod for breast cancer drug Palbociclib
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd